Molecular biology and the staging of prostate cancer

Annals of the New York Academy of Sciences

Volumn 1028, Issue , 2004, Pages 294-312

  Marandola, Paolo ^a   Bonghi, A ^a   Jallous, H ^a   Bombardelli, E ^b   Morazzoni, P ^b   Gerardini, M ^a   Tiscione, D ^a   Albergati, F ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b INDENA S P A   (Italy)

Author keywords

Androgen receptor; Growth factors; Predictors; Prostate cancer; Prostate genes; Transcription factors

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; SOMATOMEDIN; STEROID 5ALPHA REDUCTASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; AGING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CELL COMMUNICATION; CELL CYCLE; CELL DIFFERENTIATION; CELL HETEROGENEITY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOMICS; HOMEOBOX; HOMEOSTASIS; HUMAN; MALE; MESENCHYME; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; POPULATION RESEARCH; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEOMICS; REGULATOR GENE; RELIABILITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 14944357682     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1322.034     Document Type: Conference Paper

References (51)

1. Z., CULIG. 2002. Basic research on prostate cancer: signal tranduction. In Prostate and Renal Cancer, Benign Prostate Hyperplasia, Erectile Dysfunction, and Basic Research (an Update). Ch.H. Bangma and D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association. City?
2. J.R. MASTERS, T.N. ALAM, C.L. FOLEY, et al. 2002. Stem cells and differentiation in human prostate cancer. In Prostate and Renal Cancer, Benign Prostate Hyperplasia, Erectile Dysfunction, and Basic Research (an update). Ch.H. Bangma and D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association.
3. MCNEAL, J.E. 1968. Regional morphology and pathology of the prostate. Am. J. Clin. Pathol. 49(3): 347-351.
4. GOHAGAN, J.K., P.C. PROROK, B.S. KRAMER & J.E. CORNETT. 1994. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J. Urol. 152: 1905-1909.
5. DE KONING, H.J., A. AUVINEN, A. BERENGUER-SANCHEZ, et al. 2002. European Randomized Screening for Prostate Cancer (ERSPC) trial, International Prostate Cancer Screening trials Evaluation Group. Large-scale randomised prostate cancer screening trials: programm performances in the ERSPC trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int. J. Cancer 97: 237-244.
6. CATALONA, W.J., D.S. SMITH, T.L. RATLIFF, et al. 1991. Measurement of prostate-specific antigen in serum as a sceening test for prostate cancer. N. Engl. J. Med. 324: 1156-1161.
7. CATALONA, W.J., J.P. RICHIE, J.B. DEKERNION, et al. 1994. Comparison of prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol. 152: 2031-2036.
8. VIS, A.N. 2002. European Randomized Study of Screening for Prostate Cancer, Study Group Rotterdam. In Prostate and Renal Cancer, Benign Prostate Hyperplasy, Erectile Dysfunction and Basic Research (an update). C.H. Bangma & D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association. City?
9. A. HAESE, H. HULAND & H. LILJA. 2002. Diagnostic markers for prostate cancer detected in serum, plasma or blood: prostate-specific antigen forms and human kallikrein 2 for early detection and staging. In Prostate and Renal Cancer, Benign Prostate Hyperplasia, Erectile Dysfunction and Basic Research (an update). C.H. Bangma & D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association.
10. KLOTZ, L. 2002. Expectant management with selective delayed intervention for favourable-risk prostate cancer. In Prostate and Renal Cancer, Benign Prostate Hyperplasy, Erectile Dysfunction and Basic Research (an update). C.H. Bangma & D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association.
11. ADOLFSSON, J., J. CARSTENSEN & T. LOWHAGEN. 1992. Deferred treatment in clinically localized prostate carcinoma. Br. J. Urol. 69: 183-187.
12. LU-YAO, G.L. & S.L. YAO. 1997. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 349: 906-910.
13. HAMDY, F.C. 2002. Screening for prostate cancer: views from the UK and the rest of the world. In Prostate and Renal Cancer, Benign Prostate Hyperplasy, Erectile Dysfunction and Basic Research (an update). C.H. Bangma & D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association.
14. VIS, A.N., R.F. HOEDEMAEKER, T.H. VAN DER KWAST, et al. 2001. Defining a window opportunity in screening for prostate cancer; validation of a predictive tumor classification model. Prostate 46: 154-162.
15. MCNEAL, J.E. 1981. The zonal anatomy of the prostate. Prostate 2(1): 35-49.
16. MCNEAL, J.E. 1968. Regional morphology and pathology of the prostate. Am. J. Clin. Pathol. 49(3): 347-357.
17. LEAV, I., J.E. MCNEAL, P.W. KWAN, et al. 1996. Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 29: 137-145.
18. COOPER, C.S., P.J. PERRY, A.E. SPARKS, et al. 1998. Effect of exogenous testosterone on prostate volume, serum-end semen prostate specific antigen levels in healthy young men. J. Urol. 159: 441-443.
19. KAUFMAN, J.M. & A. VERMEULEN. 1997. Declining gonadal function in elderly men. Baillière's Clin. Endocrinol. Metab. 11: 289-309.
20. MORLEY, J.E., F.E. KAISER, H.M. PERRY, III, et al. 1997. Longitudinal changes in testosterone, luteinizing hormone, follicle-stimulating hormone in healthy older men. Metabolism 46: 410-413.
21. ANDERSON, J. 2003. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int. 91: 455-336.
22. LUO, J., D.J. DUGGAN, Y. CHEN, et al. 2001. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61: 4683-4688.
23. ZIAUDDIN, J. & D.M. SABATINI. 2001. Microarrays of cells expressing defined cDNAs. Nature (London) 411: 107-110.
24. VALVE, E.M., M.T. NEVALAINEN, M.J. NURMI, et al. 2001. Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab. Invest. 81: 815-826.
25. TANAKA, A., A. FURUYA, M. YAMASAKI, et al. 1998. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immuno-histochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF8. Cancer Res. 58: 2052-2056.
26. SONG, Z., W.C. POWELL, N. KASAHARA, et al. 2000. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res. 60: 6730-6736.
27. GUO, Y. & N. KYPRIANOU. 1998. Overxpression of transforming growth factor: βI receptor type II restores transforming growth factor βI sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 9: 185-193.
28. KIM, I.Y., H.J. AHN, D.J. ZELNER, et al. 1996. Loss of expression of transforming growth factor β type I and II receptors correlates with tumor grade in human prostate cancer tissue. Clin. Res. 2: 1255-1261.
29. PRINS, G.S., M.H. JUNG, R.L. VELLANOWETH, et al. 1996. Age-dependent expression of the androgen receptor gene in the prostate differentiation and hyperplasia. Dev. Genet. 18: 99-106.
30. CHAN, J.M., M.J. STAMPER, E. GIOVANUCCI, et al. 1998. Plasma insuline-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566.
31. CUNHA, G.R., S.W. HAYWARD, Y.Z. WANG & RICKE WA. 2002. Role of the stromal microenvirnment in carcinogenesis of the prostate. In Prostate and Renal Cancer, Benign Prostate Hyperplasy, Erectile Dysfunction and Basic Research (an update). C.H. Bangma & D.W.W. Newling, Eds. Seventh Congress of the Dutch Urological Association. City?
32. GARRET, R.H. & G.M. GRISHAM. 1995. Molecular aspects of cell biology. Hartcourt Brace College Publishers. Fort Worth.
33. HEATH, J.K. 1993. Growth factors. IRL Press. Oxford.
34. LODISH, H., D. BALTIMORE, A. BERK, et al. 1995. Molecular Biology. Scientific American Books. New York.
35. COOKE, P.S., P. YOUNG & G.R. CUNHA. 1991. Androgen receptor expression in developing male reproductive organs. Endocrinology 128: 2867-2873.
36. MONTIE, J.E. & K.J. PIENTA. 1994. Review of the role of androgenic hormones in the epidemiology of benign hyperplasia and prostate cancer. Urology 43: 892-899.
37. VISAKORPI, T., E. HYYTINEN, P. KORVISTO, et al. 1995. In vivo amplification of the androgen receptor gene and the progression of human prostate cancer. Nat. Genet. 9: 401-406.
38. RISBRIDGER, G., H. WANG, M. FRYDENBERG, et al. 1991. The metaplastic effects of estrogen prostate epithelium:proliferation of cells with basal cell phenotype. Endocrinology 128: 2874-2879.
39. JUNG-TESTAS, I., M.T. GROYER, J. BRUNER-LORAND, et al. 1981. Androgen and estrogen receptors in rat ventral prostate epithelium and stroma. Endocrinology 109: 1287-1289.
40. CLEUTJENS, C.B., K. STEKETEE, C.C. VAN EEKELEN, et al. 1997. Both androgen receptor and glucocorticoid receptor are be able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 138: 5293-5300.
41. SIMONS, J., W. NELSON, J. NEMUNAITIS, et al. 2002. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Presented at annual meeting of American Society of Clinical Oncology.
42. SANDA, M.G., D.G. SMITH, L.G. CHARLES, et al. 1999. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53: 260.
43. EDER, J.P., P.W. KANTOFF, K. ROPER, et al. 2000. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6: 1632.
44. GULLEY, J., A.P. CHEN, W. DAHUT, et al. 2002. Phase 1 study of a vaccineusing recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53: 109.
45. JONES, J.I. & D.R. CLEMMONS. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16: 3-34.
46. KANETY, H., Y. MADJAR, Y. DAGAN, et al. 1993. Serum insulin-like grwth factor-binding protein-2 (IGFBF-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 77: 229-233.
47. BYRNE, R.L., H. LEUNG & D.E. NEAL. 1996. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br. J. Urol. 77(5): 627-633.
48. LANE, D.P. 1992. p53, guardian of the genoma. Nature 358: 15-16.
49. VOGELSTEIN, B. & K.W. KINZLER. 1992. p53 function and dysfunction. Cell 70: 523-526.
50. HEIDENBERG, H.B., J.P. SESTERHENN, J.P. GADDIPATI, et al. 1995. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154: 414-421.
51. FEBBO, P.G. & M.A. BROWN. 2001. Nuclear receptors in normal prostatic growth and disease. In Prostate Cancer: Principles and Practice. P.W. Kantoff, P.R. Carroll, A.V. D'Amico, et al., Eds.: ch. 3. Lippincott Williams & Wilkins. Philadelphia.